Fondazione Toscana Gabriele Monasterio

The medical center is at the forefront of cardiovascular imaging research, focusing on innovative diagnostic tools for Coronary Artery Disease (CAD). The development of novel tracers like SYN2 for Positron Emission Tomography (PET) enhances the accuracy of CAD detection, offering significant improvements over traditional methods.

• Coronary Artery Disease
• Positron Emission Tomography

These advancements contribute to more precise and early diagnosis, potentially improving patient outcomes through timely intervention.

Specializing in the treatment of chronic migraine, the center is pioneering studies on the efficacy of Dysport® for migraine prevention. This research aims to reduce the frequency of migraine episodes, offering new hope for patients suffering from this debilitating condition.

• Chronic Migraine
• Botulinum Toxin Therapy

By exploring alternative therapeutic options, the center is enhancing the quality of life for migraine sufferers.

The center is advancing the understanding and treatment of hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF). Research on aficamten and MYK-224 focuses on improving safety and tolerability, offering new therapeutic avenues for these complex conditions.

• Hypertrophic Cardiomyopathy
• Heart Failure with Preserved Ejection Fraction

These studies are crucial in developing effective management strategies for patients with these challenging heart conditions.

Research at the center includes innovative approaches to treating acute myocarditis, particularly in patients with mildly reduced ejection fraction. The MYTHS-MR study investigates the potential benefits of steroid therapy, aiming to improve cardiac function and patient prognosis.

• Acute Myocarditis
• Steroid Therapy

This research is pivotal in refining treatment protocols and enhancing recovery in myocarditis patients.

The center is a leader in the study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM), focusing on the safety and efficacy of treatments like ION-682884 and acoramidis. These studies aim to reduce cardiovascular events and improve patient outcomes.

• Transthyretin-Mediated Amyloid Cardiomyopathy
• Cardiac Amyloidosis

By advancing therapeutic options, the center is making significant strides in managing this complex condition.

Focusing on atrial fibrillation and percutaneous interventions, the center explores the efficacy of single versus dual antiplatelet therapy post-left atrial appendage closure. This research is crucial in optimizing treatment strategies to minimize complications.

• Atrial Fibrillation
• Antiplatelet Therapy

These studies aim to enhance patient safety and improve procedural outcomes in interventional cardiology.

The center is dedicated to improving the management of pulmonary arterial hypertension (PAH) through studies on macitentan and sotatercept. These trials focus on long-term efficacy and safety, aiming to extend patient survival and quality of life.

• Pulmonary Arterial Hypertension
• Macitentan and Sotatercept

By exploring new treatment paradigms, the center is at the forefront of PAH research and patient care.